BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Massive Bio Targets South Korea Expansion for AI-Powered Oncology Trial Matching

US healthtech company Massive Bio has appointed international business development consultancy Intralink to support its expansion into South Korea and buil...

September 21, 2026 | News

Why 10,000 Koreans a Year Still Fly Abroad for Stem Cell Treatment

METHOD IN BRIEF This feature expands entry 21 of our year-end count, 2026 in 26 Numbers. Every figure is cited to a regulator publication, offi...

September 21, 2026 | Analysis

AstraZeneca, Daiichi Sankyo’s ENHERTU Cuts Disease Progression Risk by 37% in HER2-Mutant Lung Cancer

AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial...

September 16, 2026 | News

Rznomics Advances High-Efficiency Circular RNA Production with Engineered STS Technology

Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced a major breakthrough in t...

September 08, 2026 | News

Alteogen, Novartis Ink Up to $3.2B Deal for Subcutaneous Biologics Using ALT-B4

Novartis obtains rights to develop and commercialize subcutaneous formulations for multiple products utilizing ALT-B4 Alteogen's fourth licensing agreem...

September 04, 2026 | News

Samsung Biologics to Raise KRW 3 Trillion to Fund PolyPeptide Acquisition and Manufacturing Expansion

Samsung Biologics announced a rights offering to raise an expected aggregate amount of KRW 3 trillion to fund investments in the company's three-dimensiona...

August 31, 2026 | News

Celltrion Launches 300 mg Omlyclo Omalizumab Biosimilar Across Key European Markets

Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by ye...

August 26, 2026 | News

South Korea’s Rznomics Joins Lilly Gateway Labs in US to Accelerate RNA Gene Therapies

Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly ...

August 25, 2026 | News

South Korea’s Hanmi Pharm Licenses Obesity Drug HM17321 to Genentech in $2.3B Deal

HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including ob...

August 25, 2026 | News

Connext Completes Phase 2 Enrollment of CNT201 for Dupuytren’s Contracture

All 56 planned participants enrolled approximately five months after first patient dosing - Topline Phase 2 data expected in late 2026 - Positive d...

August 19, 2026 | News

JW Pharmaceutical’s Epaminurad Shows Statistical Superiority in Phase III Gout Trial

-JW Pharmaceutical (KRX:001060) announced that the multinational Phase 3 clinical trial of its gout treatment candidate ‘Epaminurad (code name U...

August 18, 2026 | News

Optellum, Coreline Soft Join Forces to Build Integrated AI Pathway for Lung Nodule Care

Proposed collaboration would make Coreline Soft's FDA-cleared lung nodule detection capability available through Optellum's LungOS® platform &nbs...

August 17, 2026 | News

SK bioscience Seeks South Africa Approval to Begin Phase 1b Trial of RSV Preventive Antibody RSM01

Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 months Company expands its global portfo...

August 17, 2026 | News

Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic

Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen...

August 07, 2026 | News

Stay Connected